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Abstract
Background: COVID-19 has brought an unprecedented challenge to healthcare services. The authors’ COVID-adapted pathway for
suspected bowel cancer combines two quantitative faecal immunochemical tests (qFITs) with a standard CT scan with oral preparation
(CT mini-prep). The aim of this study was to estimate the degree of risk mitigation and residual risk of undiagnosed colorectal cancer.
Method: Decision-tree models were developed using a combination of data from the COVID-adapted pathway (April–May 2020), a lo-
cal audit of qFIT for symptomatic patients performed since 2018, relevant data (prevalence of colorectal cancer and sensitivity and
specificity of diagnostic tools) obtained from literature and a local cancer data set, and expert opinion for any missing data. The con-
sidered diagnostic scenarios included: single qFIT; two qFITs; single qFIT and CT mini-prep; two qFITs and CT mini-prep (enriched
pathway). These were compared to the standard diagnostic pathway (colonoscopy or CT virtual colonoscopy (CTVC)).
Results: The COVID-adapted pathway included 422 patients, whereas the audit of qFIT included more than 5000 patients. The risk of
missing a colorectal cancer, if present, was estimated as high as 20.2 per cent with use of a single qFIT as a triage test. Using both a
second qFIT and a CT mini-prep as add-on tests reduced the risk of missed cancer to 6.49 per cent. The trade-off was an increased
rate of colonoscopy or CTVC, from 287 for a single qFIT to 418 for the double qFIT and CT mini-prep combination, per 1000 patients.
Conclusion: Triage using qFIT alone could lead to a high rate of missed cancers. This may be reduced using CT mini-prep as an
add-on test for triage to colonoscopy or CTVC.
Introduction
COVID-19 has brought unprecedented challenges to health and so-
cial services. The standard diagnostic pathway for suspected colo-
rectal cancer (CRC) was severely curtailed at the onset of the
pandemic with the majority of hospitals missing cancer targets1.
The screening service was halted for a period and there was a sig-
nificant reduction in clinic visits, treatment initiation and follow-up
across the board. Whilst vaccination programmes have started, it is
clear that the pandemic will continue to restrict cancer diagnostic
and treatment services due to ongoing requirements for distancing,
ventilation and sanitation. Data are emerging that the COVID-19
pandemic may have lasting effects in delayed diagnosis and loss of
lives and life-years2–4.
Many institutions have proposed alternative strategies to cir-
cumvent this situation5–7. One of the main approaches has been
to use a quantitative faecal immunochemical test (qFIT) to strat-
ify risk and prioritize patients for the limited number of endo-
scopic or radiological investigations available. Recently a few
studies have advocated that this test could be used as a rule-out
test for CRC, citing high negative predictive value8,9.
Whilst new measures are required to rationalize diagnostic
resources and allocate tests to those who are most likely to have
pathology, the sensitivity of the qFIT remains low compared with the
established diagnostic tools in symptomatic patients. False-negative
results, using qFIT as a single diagnostic test at a threshold of 10 mg
haemoglobin/g faeces (mg/g), result in missed cancers10. Predictive
value is dependent on disease prevalence and high negative predic-
tive value is expected given the CRC prevalence is less than 50 per
cent, thus it should not be treated as a marker of diagnostic accu-
racy11. Patients often do not return the test or do so with substantial
delay12, for a variety of reasons, and thus gatekeeping patients’ ac-
cess to services will unnecessarily disadvantage some patients.
The Western General Hospital and University of Edinburgh
have been operating a COVID-adapted diagnostic pathway, which
combines multiple qFITs and a standard CT scan with oral prepa-
ration without rectal insufflation (CT mini-prep) to rule out gross
colorectal pathology13. This iterative re-evaluation strategy could
be important, not only to define the potential trade-offs but to
aid clinical decision making when implementing this approach.
This paper aimed to develop models to calculate the degree of
risk mitigation and estimate residual risk of CRC of the COVID-
adapted pathway, considering selected alternative patterns of di-
agnostic pathways, and comparing them against the pre-COVID
conventional diagnostic pathway.
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Methods
Decision-tree models were developed using a combination of
data from the COVID-adapted pathway and a large local audit of
the use of qFIT in symptomatic patients, literature review of diag-
nostic test accuracy and expert opinion.
The local audit of qFIT for symptomatic patients has been
running since 2018 at NHS Lothian. qFIT has been used as agnos-
tic of primary care decisionand was not utilized as a gatekeeping
tool to access secondary care. There are 85 data items that have
been collected in the local audit data set, including demo-
graphics, presenting history and symptoms, co-morbidities, blood
results at the time of referrals and the outcome of standard diag-
nostic investigations (Supplementary information ). In February
2021, some 5407 patients in the audit of symptomatic patients
completed at least one qFIT.
The specific data derived from the COVID-adapted pathway
were the sensitivity of CT mini-prep to diagnose grossly abnormal
pathology, mainly CRC. CRC detection rate at the unit was calcu-
lated from a data set compiled by South East Scotland Cancer
Network and the number of referrals to the department in pre-
ceding years. As most of the data about qFIT in the literature
were based on asymptomatic screening populations14, sensitivity
and specificity of a single qFIT were based on the local audit data.
HM-JACKarcanalytical system (Hitachi Chemical Diagnostics
Systems, Tokyo, Japan, supplied by Alpha Labs, Eastleigh, UK)
based in Dundee, Scotland was used to analyse all samples. The
qFIT kit was sent from a single office in secondary care. Patients
returned the test kits by post to the biochemistry lab and all sam-
ples were processed in the standardized way.
The details of the COVID-adapted pathway have been pub-
lished previously15. Briefly, patients referred by their GP under
the category of ‘urgent suspicious of cancer’ (USOC) were triaged
by colorectal consultants based on described symptoms and
other clinical information available to:
• CT scan and qFIT if deemed ’high risk’
• Only qFIT when the referral was deemed ’low risk’ or did not
meet the urgent referral criteria
• Fast-track to outpatient clinic when referral documented pal-
pable mass.
Those in the low-risk arm who had a qFIT value of 80 mg/g or
above had a CT mini-prep added. Given the paucity of data in
symptomatic populations at the start of the pandemic, the deci-
sion to use the threshold of 80 lg/g was pragmatic and based on
the Scottish bowel-screening guidelines16. Considering the ex-
treme constraints on diagnostics, it would have been counter-
productive to use the cut-off of 10 lg/g as the threshold for urgent
investigation as pooled data suggest the positivity rate is at least
23 per cent10. A second qFIT was sent to patients when the first
qFIT was returned. The rationale of the two qFITs approach was
based on results reported by others that it may enrich for the pa-
thology and reduce the number of missed CRCs17,18.
The pathway was dynamic to the return of some diagnostics af-
ter June 2020 and changes were aimed at improving CRC detection
and safeguarding; patients with qFIT values greater than 80mg/g or
equivocal CT findings underwent colonoscopy and patients with a
qFIT value between 10 and 79mg/g underwent CT colonography
(CTVC); CT mini-prep was used as a safety-net measure for those
who returned two qFIT values less than 10lg/g.
The outcomes that were investigated in this evaluation were
the risk of a missed CRC diagnosis and the proportion of referrals
requiring a colonoscopy or CTVC. Colonoscopy and CTVC were
considered equivalent for the purpose of this study. Risk of a
missed CRC was considered to be a sufficient proxy measure of
patient outcomes while number of colonoscopies or CTVCs are
the key resource constraint in the service.
Decision trees
Decision-tree models were developed based on plausible and po-
tentially desirable alternative diagnostic pathways. In all cases
the diagnostic pathway was modified to include triage testing
(one or more qFIT, CT mini-prep). The pathway scenarios in-
cluded were: option 1 – single qFIT; option 2 – two qFITs; option
3 – single qFIT and a CT mini-prep; option 4 – two qFITs and a CT
mini-prep (enriched pathway). These scenarios were compared
with the standard diagnostic pathway (colonoscopy or CTVC with
assumed 95 per cent sensitivity at best)19.
Payoffs at the terminal nodes of the decision trees were lim-
ited to two binary indicators: whether or not a missed cancer oc-
curred and whether or not a colonoscopy or CTVC was required.
Node probabilities were defined based on local audit data in NHS
Lothian as outlined above.
Sensitivity and specificity of colonoscopy, qFIT and CT mini-
prep were obtained from the audit, SCAN data, literature and, if
missing, assumptions on reasonable (best- versus worst-case) sce-
narios were made by expert opinion based on available data by
the research team (3 colorectal surgeons, 2 radiologists and 1
medical statistician). As an example, CT mini-prep was used to
rule out gross pathology and was not directly compared against
the current standard diagnostic tests (colonoscopy or CTVC) to
diagnose CRC, thus negative CT mini-prep had to be assumed
truly negative in the best scenario (the actual data of 85 per cent
to rule out gross pathology was assumed to be the sensitivity
of detecting CRC) although the authors also considered the
worst-case scenario of sensitivity of 50 per cent.
All base case parameter values are detailed in Table 1.
Assumptions regarding symptomatic patients were required as
the bulk of data regarding qFIT in the literature are based on
screening populations. Since the audit of symptomatic patients
has shown that the distribution and profile of qFIT values are dif-
ferent compared with results of symptomatic patients referred to
a tertiary colorectal centre (Western General Hospital and
University of Edinburgh), some estimates and assumptions were
required to construct models.
GP referrals are made in three categories: urgent suspicious
of cancer (USOC), urgent and routine. To estimate the target
CRC-detection rate of the COVID-adapted pathway, the preva-
lence of CRC from GP referrals was calculated from the number
of cancers diagnosed against the number of all GP referrals
received during same months in the previous years (2017–2019,
excluding those referred via bowel cancer screening). The preva-
lence was calculated per all referrals and per USOC and urgent
combined, as the latter is most likely to match the incoming GP
referrals and produce the highest yield of CRC.
Incremental diagnostic yield was defined as the probability of
a second qFIT value of 10 mg/g or greater when the first qFIT value
was less than 10 mg/g. Incremental true positives and incremental
false positives were derived from the incremental diagnostic yield
under the assumption that cases and non-cases were equally
likely to convert. Sensitivity and specificity of CT mini-prep were
estimated from local radiologists’ estimates (sensitivity 75–80 per
cent) and available data in literature (sensitivity 100 per cent,
specificity 87–95.7 per cent)20,21. However, for the base case, esti-
mates from real-time COVID-adapted pathway data were used.
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As the negative CTs were not investigated further using the cur-
rent standard tests (colonoscopy or CTVC) at the height of pan-
demic, the sensitivity and specificity of CT mini-prep from the
pathway data were based on the assumption that negative CT
did not miss gross CRC. CTs were reported in three categories:
cancer, equivocal and normal. In the base case analysis, equivo-
cal findings are assumed to be positive as this group is referred
for the same standard tests as those for the group with a positive
result. CT mini-prep sensitivity was assumed to have equivalent
diagnostic accuracy in qFIT-positive and qFIT-negative popula-
tions. The sensitivity of the model to two key parameters was ex-
plored. An alternative prevalence value was considered and CT
mini-prep test sensitivity was varied over a plausible range (from
worst-case scenario (sensitivity of 50 per cent) to the real-time
sensitivity of 85 per cent).
Decision-tree model outputs were the percentage risk of
missed cancer for cancer cases, number of missed cancers per
1000 in the pathway and number of colonoscopies required per
1000 in the pathway.
The analysis was performed using software R version 4.0.0
(http://www.R-project.org) with package ‘data.tree’.
Results
The first version of the COVID-adapted pathway was operational
during the height of pandemic in April and May 2020. In the same
months of preceding years (2017–2019), the average rate of CRCs
detected for all the referrals (excluding bowel cancer screening
but including routine referrals) was 3.8 per cent. When the refer-
rals were restricted to a combination of USOC and urgent refer-
rals (excluding bowel cancer screening), the average rate was 9.4
per cent.
Based on these figures, 3.8 per cent has been set as the lowest
detection rate, 10.0 per cent as highest possible rate (and worst-
case scenario) and 6.6 per cent (average of 3.8 and 9.4 per cent) as
likely local CRC detection rate from combined USOC and urgent
referrals, taking into account data from the literature (around 7
per cent)22,23.
Some 325 CT mini-preps were performed in the COVID-
adapted pathway. Equivocal CTs were examined by two consul-
tant radiologists. The sensitivity of detecting cancer was between
71.4 (equivocal to negative) and 85.7 per cent (equivocal to posi-
tive), assuming all normal CTs were truly normal. With these
caveats in mind, the sensitivity of CT mini-prep included in the
model sensitivity analysis was set between 50 (worst-case sce-
nario) and 85.7 per cent (base case scenario).
The sensitivity of the qFIT for detecting cancer at the thresh-
old of 10 mg/g was set as 82.5 per cent for the decision-tree model
based on the authors’ local audit data of symptomatic patients
over the previous year, which fluctuated between 80 and 85 per
cent, in keeping with published data of qFIT sensitivity for symp-
tomatic people24,25. The incremental diagnostic yield was 6–8 per
cent based on the authors’ current pathway operation, which
possibly offers ‘enrichment’ for pathology, that is, enhances the
chance of finding a pathology.
Base case results
Risk of missed cancer and rate of colonoscopies for each of the al-
ternative pathway scenarios are reported in Table 2 and Fig. 1.
The risk of missing a cancer, if present, was as high as 20.2 per
cent with a single qFIT at the threshold of 10 mg/g used as the sole
triage test. This is equivalent to approximately 13 missed cancers
per 1000 patients that are evaluated using this diagnostic path-
way. Using both a second qFIT and a CT mini-prep as add-on
tests, the estimated risk of missed cancer reduced to 6.49 per
cent, or approximately four missed cancers for every 1000
patients on the pathway. The use of CT mini-prep as an add-on
test is predicted to decrease the number of missed cancers sub-
stantially compared with adding a second qFIT. The trade-off for
the use of the add-on tests is an increased rate of colonoscopy or
CTVC, from 287 for a single qFIT to 418 for double qFIT and CT
mini-prep combination, per 1000 patients on the pathway.
Sensitivity analysis results
Figure 2 shows the risk of missing cancer across a range of CT
mini-prep test sensitivity values. As expected, the prevalence of
CRC among the referred patients influences the rate of missed
cancers and number of colonoscopies or CTVC required.
Diagnostic outcomes under scenarios of 3.8 and 10 per cent prev-
alence are displayed in Table 3. Although missed CRCs are in-
creased substantially at higher prevalence, the number of
colonoscopies or CTVCs shows only a modest increase as the
large majority of patients in the pathway do not have CRC.
This scenario explored the impact of assuming CT mini-prep
sensitivity to be as low as 50 per cent. This would result in an in-
crease in the probability of missing a cancer to 12.61 and 10.24
per cent for options 2 and 4 respectively (8.32 and 6.75 missed
cancers per 1000 patients on the pathway). This is substantially
worse than the base case value although still fewer missed CRCs
Table 1 Base case parameter values and sources
Parameter Value Source
Prevalence 0.066 Audit, SCAN data
Colonoscopy sensitivity 0.95 Literature12,13
Colonoscopy specificity 0.99 Literature12,13
qFIT 1 sensitivity (>10 mg/g) 0.84 Audit
qFIT 1 specificity (>10mg/g) 0.752 Audit
qFIT 2 case incremental yield 0.08 Audit
qFIT 2 incremental TP 0.05 Assumption
qFIT 2 incremental FP 0.072 Audit data and assumptions*
CT mini-prep sensitivity 0.857 COVID-adapted pathway data and expert opinion assumptions†
CT mini-prep specificity 0.914 COVID-adapted pathway data and expert opinion assumptions†
* The rate of patients who had first quantitative faecal immunochemical test (qFIT) negative (<80mg/g) then second qFIT positive (>80mg/g) has been fluctuating
between 6 and 8 per cent throughout the data monitoring. However, there has been no cancer found to date within this group. Hence an assumption was
made that the middle value at the point of analysis could be the false positive. † Assumption made that truly negative standard CT scan with oral preparation
(CT mini-prep) did not miss a cancer, as CT mini-prep was performed to rule out gross pathology and not directly compared with standard colonoscopy or CT
virtual colonoscopy to diagnose CRC. SCAN, South East Scotland Cancer Network.
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than under the double qFIT scenario (option 3). There would also
be a slight decrease in the rate of colonoscopies or CTVCs to 335
and 400 per 1000 for options 2 and 4 respectively.
Discussion
This COVID-adapted pathway is an example of adding a triage
test sequence to an existing definitive diagnostic test26. The use
of multiple triage tests can be thought of as ‘add-on’ testing in
which a positive result at any stage leads to referral for the defini-
tive test, while a negative result will lead to further triage testing
until this pathway has been exhausted. It allows stratifying the
risk to patients, to allocate limited resources optimally, particu-
larly during the pandemic.
Various measures have been proposed to mitigate risks of miss-
ing CRCs and rationing available resources during the COVID pan-
demic. Understandably, there have been limited real-time data to
guide whether adoption of such strategies does indeed mitigate
against missing CRCs and, importantly, what residual risks are pre-
sent for patients referred on such alternative pathways.
Although qFIT has been advocated by many to be a useful tool
to ration limited diagnostics, caution was used in adopting the
single qFIT approach due to its low sensitivity as a rule-out test
in symptomatic patients. The present study shows the incremen-
tal value of adding standard CT with minimal preparation as it
drives down the risk of missing CRC by 65 per cent, compared
with a single qFIT.
The addition of a second qFIT does increase access to subse-
quent investigations, but there have been no CRCs detected in the
6.9 per cent of patients who had a positive result following an ini-
tial negative result and hence true enrichment for cancer detection
Table 2 Risk of missed cancer and colonoscopy or CT virtual colonoscopy rate, base case
Pathway scenarios Risk of cancer being
missed if present (%)
Missed cancers (rate per 1000
patients on pathway)
Colonoscopies/CTVC
(rate per 1000 patients
on pathway)
Pre-COVID 5 3.3 1000
1 – single qFIT 20.20 13.33 287
2 – single qFIT plus CT mini-prep 7.17 4.73 356
3 – double qFIT 15.45 10.2 358
4 – double qFIT plus CT mini-prep 6.49 4.29 418








Risk of cancer missed if present (%)
Missed cancer (rate per 1000 patientson pathway
2–Single qFIT & CT
mini-prep
3–Double qFIT 4–Double qFIT & CT
mini-prep
Fig. 1 Risk of missed cancers according to diagnostic scenarios

























CT test sensitivity value (%)
Double qFIT & CT min-prep
Single qFIT & CT mini-prep
70.0 80.0 85.7
Fig. 2 Sensitivity analysis of standard CT scan with oral preparation
qFIT, quantitative faecal immunochemical test; CT mini-prep, standard CT
scan with oral preparation
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cannot be calculated at this stage. Therefore, determining the
value of performing double qFIT needs a longer follow-up and fur-
ther data collection. Risk calculation could be further optimized by
incorporating nodal information such as existing risk factors for
CRC (previous advanced polyps, genetic disposition), blood results
(haemoglobin, platelets) and itemized symptoms. The combination
of double qFIT and CT mini-prep is substantially cheaper com-
pared with a single colonoscopy with a similar risk of missing can-
cer (6.5 per cent versus 5 per cent for colonoscopy). Prior to the
pandemic the commonest triage outcome was to offer ‘direct to
test’ with minimal gatekeeping. The data presented here suggest
one could further reduce the number of colonoscopies required
without compromising CRC detection rate. Robust analysis of
cost-effectiveness will require additional data regarding impact on
health resource use in the long term, such as repeated presenta-
tion, follow-up investigations and treatment costs.
The data give transparency in terms of risks with each scenario
used and the reasoning required to reach a decision about the
most appropriate form of triage, given the constraints faced by the
service. This information is also useful to inform GPs and patients
appropriately about this alternative pathway as a reasonable op-
tion in the current resource-limited situation and give reassurance.
The major limitation of this analysis is lack of a head-to-head
comparison of alternative and standard diagnostic pathways. In
the absence of a randomized controlled trial or comparative
study, data were retrieved from a large local audit investigating
the use of qFIT for symptomatic patients with established out-
comes by standard diagnostic tools. Clinical decisions must be
made amidst a resource-constrained situation during the ongo-
ing pandemic, thus the residual risks were calculated based on
modelling assumptions to monitor the performance of the
adapted pathway. Direct evidence could be obtained in the future
from data collected in a prospective cohort study design in which
patients receive all triage tests as well as the reference diagnostic
test. An important caveat to the present approach, which miti-
gated risk by achieving similar CRC detection rates compared
with previous years, was that referrals were decreased by 50 per
cent, highlighting the likelihood of undetected cancers15.
Triage using qFIT alone leads to an unacceptably high rate of
missed CRCs. This may be reduced effectively by using CT mimi-
prep as an add-on test for triage to colonoscopy or CTVC. There is a
need to gather more data on the diagnostic accuracy of the com-
bined qFIT and CT pathway to validate this approach and provide
confidence in the protocol.
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